Alkem Arise Online Quiz August'18

20 Questions | Total Attempts: 168

SettingsSettingsSettings
Alkem Arise Online Quiz August

.


Questions and Answers
  • 1. 
    What’s the full form of DDSI?
    • A. 

      A. Disintegrant Diluent Surfactant Indigenous Technology

    • B. 

      B. Dissolution Dispersion Sure Indigenous Technology

    • C. 

      C. Dispersion Dissolution Surfactant Indigenous Technology

    • D. 

      D. Dispersion Disintegration Surfactant Technology

  • 2. 
    The DDSI Technology ensures particle size of Cefpodoxime less than
    • A. 

      15 microns

    • B. 

      10 microns

    • C. 

      20 microns

    • D. 

      25 microns

  • 3. 
    The DDSI Technology in Swich ensures unique Hydrophillic Polymer of cefpodoxime for
    • A. 

      Faster Onset of Action

    • B. 

      Faster Dissolution

    • C. 

      Faster Absorption

    • D. 

      Both (a) & (b)

  • 4. 
    The dissolution of Swich 100DT takes place within-
    • A. 

      25 minutes

    • B. 

      25 Seconds

    • C. 

      30 minutes

    • D. 

      30 seconds

  • 5. 
    What’s the full form of NEST?
    • A. 

      Ns Enteric Sure technology

    • B. 

      N Sure enteric technology

    • C. 

      Ns Enteric Super technology

    • D. 

      N Super Enteric technology

  • 6. 
    Each 5ml of XPect-LS contains-
    • A. 

      Levosalbutamol 1mg + Ambroxol 50mg + Guaiphenesin 50mg

    • B. 

      Levosalbutamol 1mg + Ambroxol 30mg + Guaiphenesin 50mg

    • C. 

      Levosalbutamol 1mg + Ambroxol 30mg + Guaiphenesin 100mg

    • D. 

      Levosalbutamol 1mg + Ambroxol 50mg + Guaiphenesin 100mg

  • 7. 
     WHO recommends periodic deworming with Noworm as
    • A. 

      3 monthly administration for 18 months leads to reduction in STH.

    • B. 

      4 monthly administration for 20 months leads to reduction in STH

    • C. 

      3 monthly administration for 21 months leads to reduction in STH.

    • D. 

      4 monthly administration for 12 months leads to reduction in STH

  • 8. 
    The flavour of Noworm Tablet is
    • A. 

      Delicious Banana Flavor

    • B. 

      Delicious Chocolate Flavor

    • C. 

      Delicious Orange Flavor

    • D. 

      Delicious Mango Flavor

  • 9. 
    The dose of Noworm in children-1-2 years of age is
    • A. 

      10 ml or 1 tablet as a single dose

    • B. 

      10 ml or half tablet as a single dose

    • C. 

      5 ml or one tablet as a single dose

    • D. 

      5 ml or half tablet as a single dose

  • 10. 
    The dose of Noworm in Adult & Children above 2 years of age is
    • A. 

      10 ml or 1 tablet as a single dose

    • B. 

      10 ml or half tablet as a single dose

    • C. 

      5 ml or one tablet as a single dose

    • D. 

      5 ml or half tablet as a single dose

  • 11. 
    Full form of OST in Swich-XP is
    • A. 

      Oxygen Saver Technology

    • B. 

      Oxygen Scavenger Technology

    • C. 

      Oxidised Scavenger Technology

    • D. 

      Oxygen Scan Technology

  • 12. 
    Tazobactum in Swich-XP reduces MIC of ceftriaxone from
    • A. 

      256 mcg/ml to 4-8 mcg/ml

    • B. 

      266 mcg/ml to 2-4 mcg/ml

    • C. 

      256 mcg/ml to 2-4 mcg/ml

    • D. 

      222 mcg/ml to 2-4 mcg/ml

  • 13. 
    The full form of StyMO in Novogermina stands for
    • A. 

      Super Trained Spores & More Young Spores

    • B. 

      Selectively Trained Spores & More Young Spores

    • C. 

      Super Trained Spores & Morphologically Young Spores

    • D. 

      Selectively Trained Spores & Morphologically Young Spores

  • 14. 
    Indication for promotion of Tab. Esokem 20/40 mg is-
    • A. 

      Acid Peptic Disorders,Hyper-acidity & NSAID induced Gastritis

    • B. 

      In GERD & Dyspepsia associated with Nausea-vomiting

    • C. 

      In Functional Dyspepsia, Gastropaeresis & Refractory GERD

    • D. 

      All of the above

  • 15. 
     Indication for promotion of Cap. Esokem-D is-
    • A. 

      Acid Peptic Disorders, Hyperacidity & NSAID induced Gastritis

    • B. 

      In GERD & Dyspepsia associated with Nausea-vomiting

    • C. 

      In Functional Dyspepsia, Gastropaeresis & Refractory GERD

    • D. 

      All of the above

  • 16. 
    Indication for promotion of Cap. Esokem-L is-
    • A. 

      Acid Peptic Disorders, Hyperacidity & NSAID induced Gastritis

    • B. 

      In GERD & Dyspepsia associated with Nausea-vomiting

    • C. 

      In Functional Dyspepsia, Gastropaeresis & Refractory GERD

    • D. 

      All of the above

  • 17. 
    Tab. Esokem 20/40 mg is available with
    • A. 

      INTEL Technology-Intel Pellets with Intelligent dual coating

    • B. 

      INTEL Technology-Intel Tablet with Pellet Intelligent dual coating

    • C. 

      INTEL Technology-Intel Tablet with Tablet Intelligent dual coating

    • D. 

      INTEL Technology-Gastro-Resistant Tablets with Intelligent Dual Coating

  • 18. 
    Tab. Esokem D mg is available with
    • A. 

      INTEL Technology-Intel Pellets with Intelligent dual coating

    • B. 

      INTEL Technology-Intel Tablet with Pellet Intelligent dual coating

    • C. 

      INTEL Technology-Intel Tablet with Tablet Intelligent dual coating

    • D. 

      INTEL Technology-Gastro-Resistant Tablets with Intelligent Dual Coating

  • 19. 
    Rifakem offers inhibition of bacterial Translocation in
    • A. 

      Cirrhosis related Bacterial Complication

    • B. 

      HE

    • C. 

      IBS-D & Crohn’s disease

    • D. 

      Infectious Diarrhoea

  • 20. 
    Rifakem manufactured indigenously in
    • A. 

      MCC approved plant

    • B. 

      UK MHRA approved plant

    • C. 

      USFDA approved plant

    • D. 

      TGA approved plant

Back to Top Back to top